BUSINESS
Galaxy Surfactants: Limited downside risk
Among the key challenges for the company in the coming quarters is the exposure to the US, which constitutes about 10 percent of sales
BUSINESS
Sudeep Pharma IPO: A pricey play on opportunity in drug raw materials
The company’s RHP mentions that more than 80% of the excipients used in India are imported, with China being a major supplier. This underlines a significant opportunity for import substitution
BUSINESS
HEG: Why we remain constructive on this graphite player
Among the key factors to watch are a demerger of HEG Greentech, the demand-supply balance of steel and graphite electrodes in China, and the steel industry utilisation levels in the US
BUSINESS
Sai Life Sciences: Getting positioned for complex offerings
The company is collaborating with large pharma clients on ADC chemistry. ADCs are a class of complex molecules used in targeted cancer therapy
BUSINESS
Divi’s Lab: Time to take some profit off the table?
With a cash balance of more than Rs 3,200 crore, the company appears well-positioned for further investments to tap upcoming opportunities
BUSINESS
Syngene: Is the worst of worries priced in?
The company is working on growth levers, such as expanding biologics manufacturing in Bengaluru, investing in clinical capabilities for peptides, and foraying into clinical trials opportunity.
BUSINESS
Sun Pharma Q2 steady — Should investors pop the stock pill?
While US generic sales would remain soft due to the reduced contribution of Revlimid, innovative medicine sales are expected to do well.
BUSINESS
Navin Fluorine: Improved margin profile boosts confidence
CDMO orders from European CDMO/innovators, a favourable demand-supply scenario for refrigerant gases, and partnership with Chemours will largely determine the company’s growth in the coming quarters
BUSINESS
Cipla: Emerging markets to lead growth in the near term
Distribution collaboration with Eli Lilly for Mounjaro is a key factor to watch
BUSINESS
Fed chair’s commentary on inflation risk augurs well for equities
Outperformance of Indian equities on the cards, but USD/INR may remain rangebound
BUSINESS
SRF: Chemicals business to remain key driver
While agrochemicals pose challenges due to the imports from China, order deferment, and US tariffs, off-take for new agro products, along with better realisations for refrigerants, should be helpful
BUSINESS
Dr Reddy’s: Is the weight loss drug the next big opportunity?
The company plans to launch the injectable version of Semaglutide in a number of countries, starting with Canada in January 2026. India and Brazil will follow
BUSINESS
Laurus Labs: Is the healthy growth already priced in?
The CDMO business for small molecules grew 58 percent YoY in Q2FY26, helped by a ramp-up in sales from new manufacturing assets
BUSINESS
Acutaas Chemicals: Margin guidance upgrade adds to the shine
The company continues to invest in the semiconductor and battery chemicals businesses, and the next fiscal is expected to witness traction from these segments
BUSINESS
SRF: Safeguards against China’s dumping provide a cushion
The global phase-down of HFCs and the imposition of ADDs are expected to keep realisations from refrigerant gases firm. The near-term domestic demand trigger is the mandate for in-cabin ACs for commercial vehicles.
BUSINESS
What does the new US tariff salvo mean for Indian pharma?
The diktat could be positive for local generic drug companies
BUSINESS
Pace Digitek IPO is a play on energy storage opportunity
The company seems to be geared up for opportunities in the energy storage space. It aims to double BESS capacity to 10 GW in the next two years. It's also bidding for tenders in this space
BUSINESS
HEG: Will it benefit from the shift in China’s policy stance?
The anti-involution policy of China, which aims at curbing excessive competition among companies and reducing overcapacity, augurs well for HEG
BUSINESS
What's in store for Indian investors as Fed resumes the rate-cut cycle?
A tactical rebound in Indian equities and the rupee is likely
BUSINESS
What does the new US Biosecure draft Act mean for the Indian CRDMO industry?
Early enactment would compel the US biotech/pharma industry to cut reliance on China
BUSINESS
ITC: How does the new GST rate structure unfold for the cigarette business?
A flat GST on retail sales price will enhance pricing stability, and lower tax evasion, resulting in a predictable tax environment
BUSINESS
GST reforms: Push for natural ingredients in the flavours and fragrance industry
Lower GST rates for natural menthol and its derivatives, but higher for non-natural ingredients
BUSINESS
GST rate cuts to benefit players across the healthcare sector
Rates have been pruned for drugs used in chronic diseases as also medical devices and hospital chains
BUSINESS
Balaji Amines: Competitive intensity remains elevated
Favourable outcome of dumping probes appears to be the key growth catalyst in the near term
